Search Results - "Buggisch, Peter"

Health-Related Quality of Life in Previous Versus Current Opiate Users Receiving HCV Therapy: Registry-Based Evidence.

Authors: Specka, Michael Christensen, Stefan Buggisch, Peter et al.

Source: Brain Sciences (2076-3425). Apr2026, Vol. 16 Issue 4, p414. 14p.

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry.

Authors: Bischoff, Jenny Mauss, Stefan Lutz, Thomas et al.

Source: Journal of Viral Hepatitis. Nov2021, Vol. 28 Issue 11, p1660-1664. 5p.

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry.

Authors: Rau, Monika Buggisch, Peter Mauss, Stefan et al.

Source: PLoS ONE. 6/16/2022, Vol. 17 Issue 6, p1-13. 13p.

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment.

Authors: Knop, Viola Hofmann, Wolf P. Buggisch, Peter et al.

Source: Journal of Viral Hepatitis. Feb2019, Vol. 26 Issue 2, p224-230. 7p.

Recompensation of Liver Cirrhosis by TIPS Reduces Epithelial Cell Death Markers, Translating Into Improved Clinical Outcome.

Authors: Piecha, Felix Jahn, Beatrice‐Victoria Köntopf, Johannes et al.

Source: Liver International. Apr2025, Vol. 45 Issue 4, p1-13. 13p.

Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice?

Authors: Christensen, Stefan Buggisch, Peter Mauss, Stefan et al.

Source: Addiction. May2018, Vol. 113 Issue 5, p868-882.

Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.

Authors: Buggisch, Peter Heiken, Hans Mauss, Stefan et al.

Source: PLoS ONE. 5/10/2021, Vol. 16 Issue 5, p1-16. 16p.

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.

Authors: Maasoumy, Benjamin Buggisch, Peter Mauss, Stefan et al.

Source: Liver International. Nov2018, Vol. 38 Issue 11, p1906-1910. 5p. 1 Chart, 1 Graph.

Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance‐associated substitutions.

Authors: Dietz, Julia Vermehren, Johannes Matschenz, Katrin et al.

Source: Liver International. Nov2020, Vol. 40 Issue 11, p2660-2671. 12p. 1 Diagram, 2 Charts, 3 Graphs.

Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.

Authors: Dietz, Julia Kalinina, Olga V. Vermehren, Johannes et al.

Source: Journal of Viral Hepatitis. Oct2020, Vol. 27 Issue 10, p974-986. 13p.

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R).

Authors: Christensen, Stefan Buggisch, Peter Mauss, Stefan et al.

Source: Substance Abuse: Research & Treatment. 3/28/2019, Vol. 13, pN.PAG-N.PAG. 1p.

Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.

Authors: Marcellin, Patrick Wong, David K Sievert, William et al.

Source: Liver International. Oct2019, Vol. 39 Issue 10, p1868-1875. 8p. 2 Charts, 1 Graph.

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R).

Authors: Hüppe, Dietrich Stoehr, Albrecht Buggisch, Peter et al.

Source: Journal of Viral Hepatitis. Oct2021, Vol. 28 Issue 10, p1474-1483. 10p.

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs.

Authors: Tacke, Frank Boeker, Klaus H.W. Klinker, Hartwig et al.

Source: Liver International. Mar2020, Vol. 40 Issue 3, p539-548. 10p. 5 Charts, 1 Graph.

Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries

Authors: Ferenci, Peter Bourgeois, Stefan Buggisch, Peter et al.

Source: Journal of Viral Hepatitis. Jun2019, Vol. 26 Issue 6, p685-696. 12p.

Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA.

Authors: Heidrich, Benjamin Wiegand, Steffen B. Buggisch, Peter et al.

Source: PLoS ONE. Oct2014, Vol. 9 Issue 10, p1-11. 11p.

Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection.

Authors: Graf, Christiana Mondorf, Antonia Knop, Viola et al.

Source: Journal of Clinical Medicine. Dec2019, Vol. 8 Issue 12, p2101-2101. 1p.

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.

Authors: Zoulim, Fabien Moreno, Christophe Lee, Samuel S. et al.

Source: Virology Journal. 1/30/2018, Vol. 15, p1-N.PAG. 11p. 1 Diagram, 3 Charts, 2 Graphs.

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.

Authors: Bourgeois, Stefan Van Vlierberghe, Hans Moreno, Christophe et al.

Source: BMC Gastroenterology. 2/10/2017, Vol. 17, p1-11. 11p. 2 Diagrams, 2 Charts, 1 Graph.

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.

Authors: Asselah, Tarik Moreno, Christophe Sarrazin, Christoph et al.

Source: PLoS ONE. 1/5/2017, Vol. 12 Issue 1, p1-16. 16p.